GeneDx Holdings (WGS) Payables (2020 - 2026)

GeneDx Holdings (WGS) has reported Payables for 7 consecutive years, with $42.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 14.52% year-over-year to $42.1 million in Q2 2026; TTM through Jun 2026 was $42.1 million, a 14.52% decrease from a year earlier, with the FY2025 full-year figure at $57.6 million, up 86.05% from the prior year.
• Payables was $42.1 million for Q2 2026 at GeneDx Holdings, down from $46.6 million in the prior quarter.
• Over five years, Payables peaked at $118.2 million in Q2 2022 and troughed at $31.0 million in Q4 2024.
• A 5-year average of $57.4 million and a median of $51.1 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables jumped 154.21% in 2022 and tumbled 57.66% in 2023, its largest moves.
• Over 5 years, Payables stood at $88.5 million in 2022, then plunged by 57.66% to $37.5 million in 2023, then declined by 17.28% to $31.0 million in 2024, then jumped by 86.05% to $57.6 million in 2025, then fell by 26.98% to $42.1 million in 2026.
• The last three Payables figures came in at $42.1 million (Q2 2026), $46.6 million (Q1 2026), and $57.6 million (Q4 2025), per Business Quant data.